Funding Disclosures in 2024

NRAS would like to thank the following companies for supporting the work of NRAS during 2024 and acknowledge financial payment of any consultancy work provided by NRAS to the work undertaken by industry partners.

Company NameProject Name/Reason for FundingMonthAmountBeneficiaryTotal 2024 Funding (ex VAT)

AbbVie LtdNRAS invited speaker at ‘ARENA’ nurse training eventMay£438.75AbbVie 
 Funding to facilitate dubbing of NRAS SMILE-RA (e-learning platform) exercise modules into South Asian languagesJuly£9,875NRAS
  £10,313.75    
Alfasigma UK LimitedTransfer of ‘We RA Priority’ campaign video content – gift in kind only, value of content gifted listed in ‘amount’.N/A£111,000NRAS 
 Corporate MembershipAugust£12,600NRAS
  £12,600
Amgen LimitedCorporate MembershipJuly£12,000NRAS 
  £12,000
AnaptysBio Inc.Corporate MembershipMay£12,600NRAS 
  £12,600
      
Biogen Idec LimitedCorporate MembershipSeptember£12,600NRAS 
     £12,600
Boehringer Ingelheim LimitedNRAS promotion & support on ILD awareness surveyMarch£1,000Boehringer Ingelheim
 NRAS invited speaker at ‘ILD Academy’ health professional training eventSeptember£1,560Boehringer Ingelheim 
 NRAS support of ‘Real World Data’ project (milestone 1)November£1,560Boehringer Ingelheim 
     £4,120
Eli Lilly and Company LimitedCorporate MembershipJanuary£12,000NRAS 
     £12,000
Inmedix Inc.‘Stress Matters’ report print & shipping costs to the USAApril£3,315Inmedix 
     £3,315
Johnson & Johnson2025 funding for Information & Support services, Right Start and PublicationsDecember£10,000NRAS 
     £10,000
Medac Pharma LLPCorporate MembershipJanuary£12,000NRAS 
 Project collaboration on injectable treatments and South Asian resources during 2023 – 2024May£7,980Co-beneficiaries 
     £19,980
Sandoz LimitedNRAS attendance at ‘Homecare Hackathon’ eventJanuary£472Sandoz 
     £472
UCB Pharma LtdCorporate MembershipMarch£12,000NRAS 
 NRAS attendance at ‘RA Advisory Board’November£600UCB
     £12,600

Total funding received from the pharmaceutical industry in 2024: £122,600.75